NIH Sets Limit on Publishing Fees for Publicly Funded Research by 2026
NIH to implement a cap on publishing fees for research funded by the government starting in 2026, aiming to reduce costs and improve access to scientific findings.
The National Institutes of Health (NIH) has announced a new policy to limit publisher fees for research funded by the government, effective by the start of Fiscal Year 2026. This initiative aims to make publishing more affordable and accessible, addressing concerns over the high costs associated with open access publishing. Currently, some top medical journals charge as much as $13,000 per article for immediate open access, and these publishers also impose substantial subscription fees on government agencies. The NIH argues that such costs lead to an unnecessary financial burden on taxpayers, as their taxes have already supported the underlying research. While the specific cap on publishing fees has yet to be disclosed, the NIH's goal is to ensure that publication costs remain reasonable across the board. This move is part of a broader effort to promote the dissemination of research findings without imposing extra financial barriers. NIH Director Jay Bhattacharya stated that this policy is a critical step in safeguarding the integrity of scientific publishing and maximizing the public benefit from federally funded research.
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Enhancing Gait Analysis with Synthetic Data: AI Models Trained on Simulated Movements Match Real-World Performance
Scientists have developed AI models for gait analysis trained exclusively on synthetic data generated through physics-based simulations. These models match or surpass traditional approaches, offering scalable solutions for diagnosing neurological and musculoskeletal disorders across diverse populations.
Breakthrough Phase III Trial Confirms Canagliflozin's Safety and Effectiveness for Treating Type 2 Diabetes in Youths
A groundbreaking Phase III trial confirms that canagliflozin is safe and effective for managing type 2 diabetes in children and adolescents, offering new hope for treatment options in this vulnerable group.
Cannabis Use Linked to Reduced Risk of Postoperative Eyesight Complication
New research suggests cannabis use may lower the risk of complications following retinal detachment surgery. Learn more about this emerging connection in ophthalmology research.